Instil Bio (TIL) Return on Sales (2020 - 2021)
Instil Bio (TIL) posted quarterly Return on Sales of 15.94% for Q2 2021, down 1375.0% year-over-year from 1.25% in Q2 2020, and down 163.9% quarter-over-quarter from 6.04% in Q1 2021.
Instil Bio (TIL) Return on Sales (2020 - 2021) Analysis & Trends
Instil Bio's Return on Sales history runs 2 years deep, the most recent figure standing at 15.94% for Q2 2021.
- In Q2 2021, Return on Sales fell 1375.0% year-over-year to 15.94%; the TTM figure through Jun 2021 stood at 15.94% (changed N/A YoY), while the FY2020 annual figure was 2.73%, changed N/A from the prior year.
- Return on Sales for Q2 2021 stood at 15.94%, down from 6.04% in the prior quarter.
- The five-year high for Return on Sales was 0.93% in Q1 2020, with the low at 15.94% in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 0.00% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -0.05% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.00% |
| 10 | Instil Bio | 51.68 Mn | 51.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -15.94% |
| Mar 31, 2021 | -6.04% |
| Dec 31, 2020 | -2.73% |
| Sep 30, 2020 | -1.40% |
| Jun 30, 2020 | -2.19% |
| Mar 31, 2020 | -0.93% |